Dexansoprazole MV in the treatment of gastroesophageal reflux disease
Abstract
Dexlensoprazole MB is the R-enantiomer of lansoprazole and is currently the only proton pump inhibitor with the new Dual Delayed Release delivery technology. The pharmacokinetics of the drug shows two peaks of release in the 12-finger and small intestine; antisecretory effect is shown in doses of 30 mg, 60 mg, and retention of intragastric pH > 4 more than 16.5 hours per day; regardless of the time of administration. Clinical studies have shown that dexlansoprazole MB is highly effective in the healing of erosive esophagitis and symptom control in patients with non-erosive reflux disease; maintains remission with prolonged use. Effective in improving the symptoms of night heartburn associated with GERD, with sleep disturbances. Dexlensoprazole MB has a similar safety profile and side effects with lansoprazole.
Read the paper
Related studies
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Tocilizumab in patients with severe COVID-19: a retrospective cohort study
- A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study
- Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study
- Are noise and air pollution related to the incidence of dementia? A cohort study in London, England
- Long COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.